Fundraising Fox
🦊/Companies
Sign in

Arcutis

NASDAQ: ARQT

Westlake Village, US · Founded 2016 · 477 employees on LinkedIn · 3 known investors

Find your way into Arcutis

Arcutis is a biopharmaceutical company focused on dermatology, developing treatments for immune-mediated skin diseases such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis. It serves patients and healthcare professionals with therapies aimed at improving drug efficacy, safety, and tolerability.

BiotechHealthtechMedical Devices

Founders & leadership

TF
Todd Franklin WatanabeExecutive
AA
Alexander AsamNamed on SEC filing
RSRicky Sun
Ricky SunNamed on SEC filingPartner at Bain Capital Life Sciences

Board

PHPatrick Heron
Patrick HeroninBoard MemberManaging Partner at Frazier Life Sciences
DEDaniel Estes
Daniel Estesin𝕏Board directorGeneral Partner at Frazier Life Sciences
JS
Jonathan SilversteinBoard director
BCBhaskar Chaudhuri
Bhaskar ChaudhuriinBoard directorSenior Advisor at Frazier Life Sciences

Investors · 3

Bain Capital Life SciencesBoston
Frazier Life SciencesPalo Alto
RA CapitalBoston

Reported raises · per SEC filings

Form D private placements

$94.5M disclosed across 1 round · 2019

▶$94.5MraisedOct 2019 · 16 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alexander AsamDirector
  • Patrick HeronDirector
  • Daniel EstesDirector
  • Ricky SunDirector
  • Jonathan SilversteinDirector
  • Bhaskar ChaudhuriDirector
  • Todd Franklin WatanabeExecutive Officer, Director
Offering amount
$94.5M
Amount sold
$94.5M
First sale
Oct 2019
Incorporated
Corporation, Delaware, 2016
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Medscape259 shared keywordsMedscape is an online platform providing medical news, clinical information, and continuing education resources to physicians and healthcare professionals globally. The platform offers CME courses, drug and disease information, and patient education across multiple specialties.

Companies competing with Arcutis for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Form 144 Arcutis Biotherapeutics, Filed by: Burnett Patrickstreetinsider.com · Aug 2026Arcutis Biotherapeutics (ARQT) Could Be 28% Undervalued As Profit And Guidance Improve - Simply Wall St Newssimplywall.st · Aug 2026Should Arcutis Biotherapeutics’ (ARQT) Strong Q2 and Higher 2026 Sales Outlook Prompt Investor Action? - Simply Wall St Newssimplywall.st · Aug 2026Arcutis Biotherapeutics (ARQT) Could Be 31% Undervalued Following Profit And Higher Guidance - Simply Wall St Newssimplywall.st · Aug 2026Arcutis Biotherapeutics Inc (ARQT) (Q2 2026) Earnings Call Highlights: Revenue Surges 59% and ...finance.yahoo.com · Aug 2026Earnings call transcript: Arcutis Biotherapeutics tops Q2 2026 revenue view By Investing.cominvesting.com · Aug 2026Arcutis Q2 2026 slides: profitability achieved, revenue guidance raised By Investing.cominvesting.com · Aug 2026Arcutis posts Q2 profit and raises 2026 sales outlook | ARQT 8-K Filingstocktitan.net · Aug 2026

Frequently asked questions

What does Arcutis do?
Arcutis is a biopharmaceutical company focused on dermatology, developing treatments for immune-mediated skin diseases such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis. It serves patients and healthcare professionals with therapies aimed at improving drug efficacy, safety, and tolerability.
Who are Arcutis's investors?
Arcutis's investors include Bain Capital Life Sciences, Frazier Life Sciences, RA Capital.
How much funding has Arcutis raised?
Arcutis has disclosed $94.5M raised across 1 round.
Where is Arcutis headquartered?
Arcutis is headquartered in Westlake Village, US.